Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Stille AB is a Swedish company specializing in premium surgical instruments and fluoroscopy tables within the health care equipment industry. Founded in 1841 by Albert Stille, it has nearly 180 years of history in manufacturing high-quality tools that simplify surgical procedures and enable minimally invasive techniques using C-arms. As the market leader in the fluoroscopy table segment, Stille AB produces advanced products like the imagiQ3 Legacy table, made of radiolucent carbon fiber for superior imaging at lower radiation levels and featuring True Free Float® technology for swift patient positioning. Its surgical instruments, including renowned scissors, offer exceptional precision, balance, and tactile feedback, developed in collaboration with surgeons. Core values of perfection, passion, and reliability guide its operations, ensuring durable, ergonomic solutions that enhance safety and efficiency in operating rooms. Partnerships with major firms like GE Healthcare, Philips, and Siemens Healthineers underscore its global significance in supporting surgeons worldwide from its headquarters in Torshälla, Sweden.
kr 21.55
kr 0.30 (-1.37%)
EOD Jun 26, 2026 · Twelve Data
14.66% operating margin is respectable but not wide. ROIC at 7.71%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 0.4% YoY. Margins deteriorated 5.5pp alongside, both lines moving the wrong way.
Free cash flow declined 74% versus the prior year, cash generation momentum has weakened. ROIC dropped from 13.27% to 7.71%, capital efficiency is deteriorating.
3.1x earnings, 6.9x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 617M
▼ -0.4% YoY
Net Income (TTM)
kr 62M
▼ -4.3% YoY
Op. Margin
15.43%
▼ -5.5pp YoY
ROIC
7.71%
▼ -5.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 28M
▼ -73.6% YoY
Op. Cash Flow (TTM)
kr 32M
▼ -61.4% YoY
Net Debt
kr 5M
Cash & Equiv.
kr 119M
3Y CAGR: +32.1%
3Y CAGR: -13.5%
Continue Research
At a P/E of 3.1 and a price-to-free-cash-flow of 6.9, Stille AB (STIL.XSTO) trades below a two-stage DCF intrinsic value of about SEK 62.11 per share, so at SEK 21.55 the stock looks undervalued (188.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Stille AB scores 71/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 62.11 per share for STIL.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 46.59. At today's SEK 21.55, that puts the stock about 188.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Stille AB scores 71 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 15.4% operating margin and a 7.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. STIL.XSTO currently trades below its estimated intrinsic value and scores 71/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.